AKR1A1

Aldehyde reductase (AKR1A1) is a member of the aldo-keto reductase superfamily, which consists of more than 40 known enzymes and proteins that includes variety of monomeric NADPH-dependent oxidoreductases, such as aldehyde reductase. Aldehyde reductase has wide substrate specificities for carbonyl compounds. These enzymes are implicated in the development of diabetic complications by catalyzing the reduction of glucose to sorbitol. Aldehyde reductase possess a structure with a beta-alpha-beta fold which contains a novel NADP-binding motif. The binding site is located in a large, deep, elliptical pocket in the C-terminal end of the beta sheet, the substrate being bound in an extended conformation. This binding is more similar to FAD- than to NAD(P)-binding oxidoreductases. AKR1A1 is involved in the reduction of biogenic and xenobiotic aldehydes and is present in virtually every tissue.

AKR1A1 Related Areas

Enzyme>>Oxidoreductase>>AKR1A1

AKR1A1 Alternative Names

RP4-697E16.2, ALDR1, ALR, ARM, DD3, MGC12529, MGC1380[Homo sapiens]

Summaries for AKR1A1

Entrez Gene summary for AKR1A1:

This gene encodes a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. This member, also known as aldehyde reductase, is involved in the reduction of biogenic and xenobiotic aldehydes and is present in virtually every tissue. Multiple alternatively spliced transcript variants of this gene exist, all encoding the same protein.

OMIM - description for AKR1A1:

Aldehyde reductase (EC 1.1.1.2) and aldose reductase (EC 1.1.1.21; 103880) are monomeric NADPH-dependent oxidoreductases having wide substrate specificities for carbonyl compounds

Wikipedia summary for AKR1A1:

Alcohol dehydrogenase [NADP+] also known as aldehyde reductase or aldo-keto reductase family 1 member A1 is an enzyme that in humans is encoded by the AKR1A1 gene.

Human AKR1A1 Protein General Information

 

• Protein names: Recommended name: Alcohol dehydrogenase [NADP(+)]
• Sequence length: 325 AA.
• Sequence similarities: Belongs to the aldo/keto reductase family.
• Subunit structure: Monomer
• Tissue specificity: Widely expressed. Highly expressed in kidney, salivary gland and liver. Detected in trachea, stomach, brain, lung, prostate, placenta, mammary gland, small intestine and lung
• Catalytic activity: An alcohol + NADP+ = an aldehyde + NADPH.

General information above from UniProt

Function for AKR1A1 Protein

UniProtKB:

Catalyzes the NADPH-dependent reduction of a variety of aromatic and aliphatic aldehydes to their corresponding alcohols. Catalyzes the reduction of mevaldate to mevalonic acid and of glyceraldehyde to glycerol. Has broad substrate specificity. In vitro substrates include succinic semialdehyde, 4-nitrobenzaldehyde, 1,2-naphthoquinone, methylglyoxal, and D-glucuronic acid. Plays a role in the activation of procarcinogens, such as polycyclic aromatic hydrocarbon trans-dihydrodiols, and in the metabolism of various xenobiotics and drugs, including the anthracyclines doxorubicin (DOX) and daunorubicin (DAUN).

Genatlas:

• AKR1A1 aldehyde (aldoketo) reductase 1, monomeric, NADPH dependent, reducing various biogenic and xenobiotic aldehyde compounds
• AKR1A1 plays an important role in detoxification of arising reactive metabolites during cell proliferation and tissues development
• NADPH-dependent oxidoreductase involved in catalyzing the reduction of aldehydes

Homology for human AKR1A1

• homolog to murine Akr1a4

Drugs for AKR1A1

Target	Drug Name	Disease	Drug Status
AKR1A1	Fomepizole	Athylene glycol or methanol poisoning	Approved

Drugs for AKR1A1 from TTD (Therapeutic Targets Database)